

THINCR Selected as One of the Global Sites for Phase 3 Pediatric Chikungunya Vaccine Trial



THINCR has been selected as one of the sites to participate in the clinical trial entitled “**A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Immunogenicity of the CHIKV VLP Vaccine in Children Aged 2 to <12 Years.**” The study is sponsored by **Bavarian Nordic**, and it has received approval from both the local **Institutional Review Board (IRB)** and the **Food and Drug Administration (FDA)**. The Investigator Meeting was held on **11–12 December 2025** at I’M Hotel in Makati City, Philippines. Representing THINCR were **Dr. Melchor Victor G. Frias IV** (Principal Investigator), **Dr. Ma. Tarcela S. Gler**, and **Dr. Dessa Jean O. Casalme**. The meeting was also attended by other investigators and study coordinators from the other 5 sites in the Philippines. Participant recruitment at the site is expected to begin in **January 2026**.